Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022256 · ClinicalTrials.gov registry record · Phase 2
Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00022256: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00022256 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022256, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as motexafin gadolinium may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of motexafin gadolinium plus radiation therapy to the brain in treating patients who have newly diagnosed glioblastoma multiforme.
Interventions
- RADIATION radiation therapy
- DRUG motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
What the finished NCT00022256 record still lists
NCT00022256 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00022256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00022256 about?
NCT00022256 is a clinical study titled "Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as motexafin gadolinium may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of motexafin gadolinium plus radiation therapy to the brain in treating patient...
What is the current status of trial NCT00022256?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00022256?
The interventions under investigation include: radiation therapy (RADIATION), motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00022256?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia